Medical Condition News

RSS

Novartis releases study results on oral calcitonin for treatment of osteoarthritis: Unigene Laboratories

Unigene Laboratories, Inc. announced today that Novartis has released information on the first of two studies on oral calcitonin for the treatment of osteoarthritis conducted by its license partner Nordic Bioscience. The recently completed Study 2301, which assesses the safety and efficacy of oral calcitonin in the treatment of knee osteoarthritis, had three co-primary endpoints.

22 Oct 2010

Idera announces IMO-3100 Phase 1 clinical trial results for autoimmune disease

Idera Pharmaceuticals, Inc. today announced results from its single-dose, dose-escalation Phase 1 clinical trial evaluating the safety and mechanism of action of IMO-3100, its lead Toll-like Receptor (TLR) 7 and TLR9 antagonist drug candidate for the treatment of autoimmune and inflammatory diseases.

22 Oct 2010

Atherotech to present VAP Cholesterol Test at OMED 2010

Atherotech Diagnostics Lab will showcase its VAP Cholesterol Test in booth 324 at the American Osteopathic Association's 115th Annual Osteopathic Medical Conference & Exposition (OMED 2010). The gathering of DOs, residents, interns, students, researchers and health care professionals will be held October 24-28 at Moscone Convention Center in San Francisco.

22 Oct 2010

Advaxis completes patient recruitment in ADXS11-001 phase II study for cervical dysplasia

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, completes recruitment of the first group of patients in its US cervical dysplasia (CIN) phase II study of ADXS11-001 as required for the planned DMSB (safety board) meeting scheduled to be held January 11, 2011.

22 Oct 2010

Celtic Pharma receives US patent for methods to treat breast, colon cancer

Celtic Pharmaceutical Holdings L.P. today announced that the U.S. Patent Office has issued U.S. patent 7,816,323, for novel methods to treat breast and colon cancers using a combination therapy of Xerecept with Avastin.

22 Oct 2010

Snoring may destroy grey matter

A new Australian study has found that snoring and troubled nights could be a warning of brain damage occurring while sleeping. The team looked at brain scans of 60 people, aged in their mid-40s and recently diagnosed with a common sleep disorder – obstructive sleep apnea. Obstructive sleep apnea often affects overweight and the obese and leads to snoring. Results showed “decreased amount of grey matter” when compared to healthy sleepers.

21 Oct 2010

Astellas suspends enrollment in ACT 5 study of KYNAPID in atrial fibrillation patients

Cardiome Pharma Corp. today announced that its co-development partner, Astellas Pharma US., Inc., has suspended patient enrollment in the ACT 5 study of KYNAPIDTM (vernakalant hydrochloride) Injection following a single unexpected serious adverse event of cardiogenic shock experienced by a patient with atrial fibrillation who received KYNAPID.

21 Oct 2010

Boston Scientific's Advanix Biliary Plastic Stents receive FDA 510(k) clearance and CE Mark approval

Boston Scientific Corporation today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration and CE Mark approval to market its Advanix™ Biliary Plastic Stents for the treatment of biliary strictures, including biliary stone disease, benign biliary strictures, and suspected and confirmed malignancies in the biliary system. The product is now available in Europe and other international markets; the Company plans to launch it in the U.S. this quarter.

21 Oct 2010

Health Canada approves ULORIC to lower serum uric acid levels in patients with gout

Takeda Canada, Inc. is pleased to announce that ULORIC® (febuxostat), an innovative oral urate-lowering therapy to lower serum uric acid levels in patients with gout is now available in Canada. This medication is the first new treatment option in more than 40 years for the approximately three per cent of Canadians who have hyperuricemia associated with gout.1 ULORIC was discovered by Teijin Pharma Limited of Tokyo and licensed to Takeda for the Canada market.

21 Oct 2010

PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).

21 Oct 2010

IDEV includes two stents to SUPERA product line for treating patients with peripheral vascular disease

IDEV Technologies, Incorporated (IDEV), an innovative leader in the development and commercialization of minimally invasive medical technologies, today announced another step in the implementation of its strategy to expand its product line for treating patients with peripheral vascular disease with the addition of two longer stents to its SUPERA product line.

21 Oct 2010

Cerenis raises €10 million in second close of Series C financing

Cerenis Therapeutics, a biopharmaceutical company specializing in the research and development of novel therapies based on HDL to treat cardiovascular and other metabolic diseases, announced today it has raised a further €10 million in a second close of its Series C financing. This takes the total funds raised in the Series C to €50 million and the total equity investment raised to date by the Company to €117 million.

21 Oct 2010

Study finds online activities does not effect long-term psychological health

After the campus shootings at Virginia Tech in 2007 and Northern Illinois University in 2008, hundreds of affected students turned to social media websites to share their grief and search for solace. A new study of these students found that their online activities neither helped nor harmed their long-term psychological health.

21 Oct 2010

ISCTM to develop solutions for CNS clinical trial methodology

The International Society for CNS Clinical Trials and Methodology (ISCTM) met recently to develop solutions to challenges facing CNS clinical trial methodology.

21 Oct 2010

Major companies phase out BPA from food and beverage packaging

Major brand name companies including Hain Celestial, H.J. Heinz, ConAgra, and General Mills are taking a leadership role in responding to consumer market shifts as awareness about health hazards of the endocrine disrupting chemical bisphenol A (BPA) in food can linings rises.

21 Oct 2010

Researcher creates novel theory about chronic depression

Chronic depression is an adaptive, reparative neurobiological process gone wrong, say two University of California, San Diego School of Medicine researchers, positing in a new theory that the debilitating mental state originates from more ancient mechanisms used by the body to deal with physical injury, such as pain, tissue repair and convalescent behavior.

21 Oct 2010

New data from ESHO/EORTC STBSG Phase III clinical study of hyperthermia

BSD Medical Corporation announced publication in Internal Medicine News Digital Network of new data from the ESHO/EORTC Soft Tissue and Bone Sarcoma Group (STBSG) Phase III clinical study of hyperthermia.

21 Oct 2010

Bonati Spine Institute supports National Breast Cancer Awareness

The Bonati Spine Institute, the leading center for the patented Bonati Spine Procedures for minimally invasive laser spine surgery, is a strong supporter of National Breast Cancer Awareness.

21 Oct 2010

$OptiNose reports positive results from study of fluticasone delivered by novel device in refractory CRS$

OptiNose reports positive results from study of fluticasone delivered by novel device in refractory CRS

Today OptiNose Inc. announced the positive results of a study evaluating the efficacy of fluticasone when delivered by the Company's novel bi-directional technology in patients with refractory chronic rhinosinusitis (CRS). The results of the study have been published in an article in the September issue of Rhinology.

21 Oct 2010

Endocrine Society's statement clarifies association between hormone therapy and breast cancer risk

Richard J. Santen, MD, lead author of The Endocrine Society's Scientific Statement on menopausal hormone therapy, can provide clarity on the association of hormone therapy and increased risk of breast cancer as reported in an article published this week in The Journal of the American Medical Association (JAMA)

21 Oct 2010

Medical Condition News

Novartis releases study results on oral calcitonin for treatment of osteoarthritis: Unigene Laboratories

Idera announces IMO-3100 Phase 1 clinical trial results for autoimmune disease

Atherotech to present VAP Cholesterol Test at OMED 2010

Advaxis completes patient recruitment in ADXS11-001 phase II study for cervical dysplasia

Celtic Pharma receives US patent for methods to treat breast, colon cancer

Snoring may destroy grey matter

Astellas suspends enrollment in ACT 5 study of KYNAPID in atrial fibrillation patients

Boston Scientific's Advanix Biliary Plastic Stents receive FDA 510(k) clearance and CE Mark approval

Health Canada approves ULORIC to lower serum uric acid levels in patients with gout

PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology

IDEV includes two stents to SUPERA product line for treating patients with peripheral vascular disease

Cerenis raises €10 million in second close of Series C financing

Study finds online activities does not effect long-term psychological health

ISCTM to develop solutions for CNS clinical trial methodology

Major companies phase out BPA from food and beverage packaging

Researcher creates novel theory about chronic depression

New data from ESHO/EORTC STBSG Phase III clinical study of hyperthermia

Bonati Spine Institute supports National Breast Cancer Awareness

OptiNose reports positive results from study of fluticasone delivered by novel device in refractory CRS

Endocrine Society's statement clarifies association between hormone therapy and breast cancer risk

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Latest News